CONMED Corporation
CONMED Corporation Fundamental Analysis
CONMED Corporation (CNMD) shows weak financial fundamentals with a PE ratio of 29.83, profit margin of 3.42%, and ROE of 4.68%. The company generates $1.4B in annual revenue with moderate year-over-year growth of 5.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 41.5/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CNMD's fundamental strength across five key dimensions:
Efficiency Score
WeakCNMD struggles to generate sufficient returns from assets.
Valuation Score
ModerateCNMD shows balanced valuation metrics.
Growth Score
ModerateCNMD shows steady but slowing expansion.
Financial Health Score
ExcellentCNMD maintains a strong and stable balance sheet.
Profitability Score
WeakCNMD struggles to sustain strong margins.
Key Financial Metrics
Is CNMD Expensive or Cheap?
P/E Ratio
CNMD trades at 29.83 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, CNMD's PEG of -1.12 indicates potential undervaluation.
Price to Book
The market values CONMED Corporation at 1.36 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.45 times EBITDA. This is generally considered low.
How Well Does CNMD Make Money?
Net Profit Margin
For every $100 in sales, CONMED Corporation keeps $3.42 as profit after all expenses.
Operating Margin
Core operations generate 8.17 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.68 in profit for every $100 of shareholder equity.
ROA
CONMED Corporation generates $2.02 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CONMED Corporation produces operating cash flow of $170.69M, showing steady but balanced cash generation.
Free Cash Flow
CONMED Corporation generates strong free cash flow of $150.88M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $4.87 in free cash annually.
FCF Yield
CNMD converts 10.78% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.83
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.36
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.02
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.81
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.14
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How CNMD Stacks Against Its Sector Peers
| Metric | CNMD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.83 | 29.43 | Neutral |
| ROE | 4.68% | 800.00% | Weak |
| Net Margin | 3.42% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.81 | 0.30 | Weak (High Leverage) |
| Current Ratio | 2.14 | 4.64 | Strong Liquidity |
| ROA | 2.02% | -17936.00% (disorted) | Weak |
CNMD outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CONMED Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
25.66%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
324.88%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
61.17%
Industry Style: Defensive, Growth, Innovation
High Growth